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Background: Prognostic assessment is important for the management of patients with acute pulmonary embolism
(APE). Pulmonary Embolism Severity Index (PESI) and simple PESI (sPESI) are new emerged prognostic assessment
tools for APE. The aim of this meta-analysis is to assess the accuracy of the PESI and the sPESI to predict prognostic
outcomes (all-cause and PE-related mortality, serious adverse events) in APE patients, and compare between these
two PESIs.
Methods: MEDLINE and EMBASE database were searched up to June 2012 using the terms “Pulmonary Embolism
Severity Index” and “pulmonary embolism”. Summary odds ratio (OR) with 95% confidence intervals (CIs) for
prognostic outcomes in low risk PESI versus high risk PESI were calculated. Summary receiver operating
characteristic curve (SROC) used to estimate overall predicting accuracies of prognostic outcomes.
Results: Twenty-one studies were included in this meta-analysis. The results showed low-risk PESI was significantly
associated with lower all-cause mortality (OR 0.13; 95% CI 0.12 to 0.15), PE-related mortality (OR 0.09; 95% CI 0.05 to
0.17) and serious adverse events (OR 0.34; 95% CI 0.29 to 0.41), with no homogeneity across studies. In sPESI
subgroup, the OR of all-cause mortality, PE-related mortality, and serious adverse events was 0.10 (95% CI 0.08 to
0.14), 0.09 (95% CI 0.03 to 0.26) and 0.40 (95% CI 0.31 to 0.51), respectively; while in PESI subgroup, the OR was 0.14
(95% CI 0.13 to 0.16), 0.09 (95% CI 0.04 to 0.21), and 0.30 (95% CI 0.23 to 0.38), respectively. For accuracy analysis,
the pooled sensitivity, the pooled specificity, and the overall weighted AUC for PESI predicting all-cause mortality
was 0.909 (95% CI: 0.900 to 0.916), 0.411 (95% CI: 0.407 to 0.415), and 0.7853±0.0058, respectively; for PE-related
mortality, it was 0.953 (95% CI: 0.913 to 0.978), 0.374 (95% CI: 0.360 to 0.388), and 0.8218±0.0349, respectively; for
serious adverse events, it was 0.821 (95% CI: 0.795 to 0.845), 0.389 (95% CI: 0.384 to 0.394), and 0.6809±0.0208,
respectively. In sPESI subgroup, the AUC for predicting all-cause mortality, PE-related mortality, and serious adverse
events was 0.7920±0.0117, 0.8317±0.0547, and 0.6454±0.0197, respectively. In PESI subgroup, the AUC was 0.7856
±0.0075, 0.8158±0.0451, and 0.6609±0.0252, respectively.
Conclusions: PESI has discriminative power to predict the short-term death and adverse outcome events in
patients with acute pulmonary embolism, the PESI and the sPESI have similar accuracy, while sPESI is easier to use.
However, the calibration for predicting prognosis can’t be calculated from this meta-analysis, some prospective
studies for accessing PESI predicting calibration can be recommended.
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Epidemiological studies showed the prevalence of acute
pulmonary embolism (APE) among hospitalized patients
in the United States, according to data collected between
1979 and 1999, was 0.4% [1]. In Europe, a total of 67,351
(in 2005), 69,234 (in 2006) and 71,223(in 2007) APE were
coded either as principal or secondary diagnosis in Ger-
man hospitals according to the data from Federal Statis-
tical Office [2]. In Asia, from a multi-center registration
study of Chinese hospitals between 1997 and 2008, a
total of 18,206 patients were confirmed with APE from
16,972,182 hospital admissions, the annual incidence was
0.1% (95% CI: 0.1% to 0.2%) [3]; while in Korean, inci-
dence of established APE was 88 (0.17%) of 50,882 iden-
tified retrospectively from patients hospitalized during a
2-year period from 2005 to 2007[4]. APE has become a
relatively common cardiovascular emergency.
The key consequences of a pulmonary thrombo-
embolic episode are haemodynamic. Large and multiple
emboli might abruptly increase pulmonary vascular re-
sistance to a level of after load which cannot be matched
by the right ventricle (RV), and sudden death may occur
[5]. In the ICOPER registry, the 14-day mortality of APE
was above 20% [6]. In the RIETE registry, at 3 months,
the cumulative rates of overall mortality and fatal PE
were 8.65% and 1.68%, respectively [7]. While in the
EMPEROR registry, the all-cause 30-day mortality rate
was 5.4% (95% CI: 4.4% to 6.6%) [8]. APE has become
one of the leading causes of preventable hospital deaths.
The mortality of APE can be predicted by haemo-
dynamic status, right ventricular dysfunction, myocardial
injury, and other clinical and routine laboratory tests.
Shock and hypotension are principal markers of high
risk of early death in APE. RV dysfunction which is
detected by echocardiography, computed tomography,
and brain natriuretic peptide (BNP) is related to inter-
mediate risk of short-term mortality in APE. Myocardial
injury in patients with APE is related to an intermediate
risk of short-term mortality, which can be detected by
troponin T or I testing [5]. While the Pulmonary Embol-
ism Severity Index (PESI) was recently found to be a
well validated and highly reliable clinical prognostic
model for patients with APE.
The PESI was designed by Aujesky D and his col-
league in 2005, which comprises 11 routinely available
clinical predictor variables with different prognostic
weights [9]. On the basis of the PESI score, each pa-
tient is classified into one of five classes (I-V), with 30-
day mortality ranging from 1.1% to 24.5%. Patients in
risk classes I and II are categorized as low-risk and in
risk classes III-V are categorized as high-risk. While the
PESI is hard to memorizes for based on 11 items, and
it’s difficult to calculate in busy emergency departments.
The simplified PESI (sPESI) was developed in 2010,which includes six of the 11 original PESI variables
[10]. Patients with none of the variables (0 points) are
categorized as low-risk; with one to six the variables
(1–6 points) are categorized as high-risk. The PESI and
sPESI are listed in the Additional file 1: Appendix 1.
The prognostic value of the PESI and sPESI has been
assessed by some studies, but has not been systematic
reviewed. We conduct this meta-analysis to assess the
accuracy of the PESI and the sPESI to predict prognostic
outcomes in APE patients. In particular, we also com-
pared the predicting accuracy between these two PESIs.
Materials and methods
Eligibility criteria
We defined studies as being eligible for inclusion in this
analysis if they met the following criteria: (1) types of
studies: observational studies ( cohort studies and case–
control studies ) were included; (2) types of participants:
population of objective diagnosis of APE with short-
term prognosis outcome were included; (3) types of out-
comes: studies included at least one of three prognostic
outcomes: all-cause mortality, PE-related mortality, ser-
ious adverse events; and a 2×2 table of outcome results
could be constructed based on low-risk PESIs or high-
risk PESIs.
Search strategy and study selection
We searched MEDLINE (PubMed, http://www.ncbi.nlm.
nih.gov/pubmed/), and EMBASE (http://www.embase.
com) up to June 2012. The search strategy included terms
of “Pulmonary Embolism Severity Index” and “Pulmonary
Embolism”. The search was limited to English- language
articles. We did not appoint limit in country, race, or pub-
lication year. To identify any additional relevant studies,
we also hand-searched conference proceedings and
scanned references of retrieved articles.
Study selection was initially performed by review of
titles and abstracts. When there was any possibility that
it might be relevant, the full text were downloaded and
then reviewed for data retrieval.
Two reviewers independently judged study eligibility
while screening the citations. Disagreements were
resolved by a third reviewer.
Quality assessment
We used Newcastle–Ottawa Scale (NOS) to assess the
quality of the included observational studies [11]. The
NOS contains eight items, categorized into three
dimensions including Selection (4), Comparability (1),
and Exposure (3). A high quality study can be awarded
a maximum of one star for each numbered item within
the Selection and Exposure categories. A maximum of
two stars can be given for Comparability. The NOS
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in the Additional file 2: Appendix 2.
Two reviewers independent assessed the quality of
studies. Disagreements were resolved by a third reviewer.
Data extraction
We collected information about study characteristics
(study year, country, study design, number of patients,
mean age, gender distribution, type of PESI, methods for
diagnosis of APE, haemodynamic status, length of
follow-up) and number of patients with the available
outcomes of all-cause death, PE-related death, serious
adverse events among low-risk or high-risk PESIs.
In this meta-analysis, all-cause mortality was considered
as the primary outcome, PE-related death, serious adverse
events were considered as the secondary outcome. Serious
adverse events were defined as any of the following:
nonfatal recurrent PE, nonfatal recurrent DVT, nonfatal
bleeding, or delayed homodynamic instability.
Data were extracted independently by two reviewers.
Any differences of opinion were resolved by discussion
and consensus reached by discussion with a third reviewer.
Statistical analysis
First, we considered high-risk PESI as a risk factor for
APE prognostic adverse outcomes. Summary OR with
95% CIs for three prognostic outcomes in low-risk PESI
versus high-risk PESI was calculated respectively. Statis-
tical heterogeneity was explored by χ2 and inconsistency
(I2) statistics; an I2 value of 50 percent or more repre-
sented heterogeneity [12]. If there was no heterogeneity,
fixed effects model was used for meta-analysis; otherwise,
a random effect model based on the DerSimonian and
Laird estimator was used [13]. Overall effects were deter-
mined using the Z test. Potential publication bias was
evaluated by the funnel plot. Subgroup meta-analyses
were performed by PESI subgroup and sPESI subgroup.
Sensitivity analysis was performed by only pooled pro-
spective studies. The first step meta-analysis was per-
formed with Review Manager (RevMan) software (version
5.0.21; Update Software Ltd, Oxford, Oxon, UK).
Second, we assess the accuracy (discriminative power)
of PESI to predict APE prognostic outcomes. If we pre-
dict low-risk PESI as good prognostic outcomes, high-
risk PESI as worse prognostic outcomes, the sensitivity
(true positive rate) and specificity (true negative rate) of
each included study was calculated compared to actual
prognostic outcomes (the so-called gold standard). And
the overall pooled sensitivity and specificity with 95%
CIs was estimated by DerSimonian and Laird’s random-
effects model [13]. In addition, summary receiver operator
characteristic (SROC) analysis was performed to examine
the interaction between sensitivity and (1-specificity) [14],
and to quantify test performance using the area under thecurve (AUC) and Q* value[15]. The second step meta-
analyses were performed with Meta DiSc 1.4 (version 0.6;
By Joseph Lau) [16].
Results
Description of included studies
Overall, 21 studies [10,17-36] were selected for this
meta-analysis described in Figure 1. Among those stud-
ies, 10 studies were prospective cohorts, 9 studies were
retrospective cohorts or case–control studies, the
remaining 2 studies didn’t mention about the study de-
sign type. Eleven studies were multi-center studies.
Countries involved in these studies were Germany,
Spain, Poland, Greece, Switzerland, USA, Belgium, Italy,
Greece, UK, Israel, and Korea. Most of the studies
(20 studies) came from Europe and North America, only
a study came form Asia. All of the 21 included studies
used the same diagnostic criteria of PE, which included
high clinical probability of PE, and confirmed by
contrast-enhanced multi detector CT or ventilation-
perfusion lung scan, or confirmed lower limb deep vein
thrombosis (DVT) by venous ultrasound. A total of 5
studies included haemodynamic stable patients, a study
included haemodynamic stable and unstable patients,
but most of the studies didn’t mention about the haemo-
dynamic status of the included patients. The length of
follow-up ranged from hospital discharge to 6 month
following admission to hospital. The NOS for methodo-
logical quality assessment of these 21 studies all scored
at 7 of 8 star, indicating good quality. The main charac-
teristics of the selected studies are reported in Table 1.
Meta-analysis
High-risk PESI as a risk factor for adverse outcomes
The association between PESI and PE adverse prognosis
outcome risk of every included study are shown in
Table 2. Data on all-cause mortality were reported in
19 studies. Five studies assessed the sPESI, 11 studies
assessed the PESI, 3 studies assessed sPESI and PESI in
the same study. A total of 50,021 patients were ana-
lyzed in the studies, including 4,991 patients with all-
cause death. There was no heterogeneity in the studies
(I2 = 0%). The pooled all-cause mortality was 2.0%
(456/22978) in patients with low-risk PESI Vs 16.7%
(4535/27043) in patients with high-risk PESI. The sum-
mary OR of patients with low-risk PESI compared with
patients with high-risk PESI was 0.13 (95% CI 0.12 to
0.15; Z=33.76, P < 0.00001) (Figure 2). The funnel plot
showed no asymmetry, which indicated no evidence of
publication bias (Figure 3A). While in subgroup analysis
for sPESI and PESI, the pooled all-cause mortality was
1.8% (180/9995) in patients with low-risk sPESI Vs
25.2%(2040/8096) in patients with high-risk sPESI, the
summary OR of patients with low-risk sPESI compared
Study or Subgroup
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Figure 1 Flow diagram showing selection of studies.
Zhou et al. Respiratory Research 2012, 13:111 Page 4 of 12
http://respiratory-research.com/content/13/1/111with patients with high-risk sPESI was 0.10 (95% CI
0.08 to 0.14; Z=15.04, P < 0.00001) (Figure 2 Above);
the pooled all-cause mortality was 2.1% (276/12983) in
patients with low-risk PESI Vs 13.2% (2495/18947) in
patients with high-risk PESI, the summary OR of
patients with low-risk PESI compared with patients
with high-risk PESI was 0.14 (95% CI 0.13 to 0.16;
Z=30.10, P < 0.00001) (Figure 2 Below).
Data on PE-related mortality were reported in 7 stud-
ies, 3 studies assessed the sPESI, and 4 studies assessed
the PESI. A total of 4,794 patients were analyzed in the
studies, including 192 patients with PE-related death.
There was no heterogeneity in the studies (I2 = 0%). The
pooled PE-related mortality was 0.5% (9/1731) in
patients with low-risk PESI Vs 6.0% (183/3063) in
patients with high-risk PESI. The summary OR of
patients with low-risk PESI compared with patients with
high-risk PESI was 0.09 (95% CI 0.05 to 0.17; Z=7.14,
P < 0.00001) (Figure 4). The funnel plot showed no
asymmetry, which indicated no evidence of publication
bias (Figure 3B). While in subgroup analysis for sPESI and
PESI, the pooled PE-related mortality was 0.4%
(3/770) in patients with low-risk sPESI Vs 5.1% (72/1404)
in patients with high-risk sPESI, the summary OR ofpatients with low-risk sPESI compared with patients
with high-risk sPESI was 0.09 (95% CI 0.03 to 0.26;
Z=4.39, P < 0.00001) (Figure 4 Above); the pooled PE-
related mortality was 0.6% (6/961) in patients with
low-risk PESI Vs 6.7% (111/1659) in patients with
high-risk PESI, the summary OR of patients with low-
risk PESI compared with patients with high-risk PESI
was 0.09 (95% CI 0.04 to 0.21; Z=5.62, P < 0.00001)
(Figure 4 Below).
Data on serious adverse events were reported in 8
studies, 4 studies assessed the sPESI, 3 studies assessed
the PESI, a study assessed sPESI and PESI in the same
study. A total of 50,021 patients were analyzed in the
studies, including 4,991 patients with serious adverse
events. There was no heterogeneity in the studies
(I2 = 36%). The pooled serious adverse events rate was
1.2% (166/13355) in patients with low-risk PESI Vs 3.5%
(761/21621) in patients with high-risk PESI. The sum-
mary OR of patients with low-risk PESI compared with
patients with high-risk PESI was 0.34 (95% CI 0.29 to
0.41; Z=12.32, P < 0.00001) (Figure 5). The funnel plot
showed no asymmetry, which indicated no evidence of
publication bias (Figure 3C). While in subgroup analysis
for sPESI and PESI, the pooled serious adverse events
Table 1 Characteristics of Selected Studies








Lankeit M, 2011 Germany, Spain,
Poland, Greece
Prospective 526 71 (55–79) 266/260 Stable 6 month 8
Sánchez D, 2011 Spain, Switzerland, USA Retrospective 1291 74 (61–80) 579/712 Stable and unstable 30 day 7
Lankeit M,2012 Germany, Spain, Greece Prospective 526 74 (61–80) 227/299 Stable and unstable 30 day 7
Righini M,2011 Switzerland, France,
Belgium
Prospective 357 mean age 64 157/200 Stable and unstable 3 month 8
Spirk D, 2011 Switzerland Prospective 369 20.9% >80 195/174 Stable and unstable 30 day 8
Vanni S, 2011 Italy Prospective 463 67% > 65 208/254 Stable and unstable in-hospital stay 8
Venetz C, 2011 Switzerland, Spain Not mentioned 15531 67 (52–77) 6227/9304 Stable and unstable 30 day 7
Hariharan P, 2011 USA Retrospective 245 57 ± 17 115/130 Stable and unstable in-hospital stay 8
Jiménez D, 2011 Spain, Switzerland,
USA, Greece
Not mentioned 591 74 (65–82) 254/337 Stable 30 day 7
Singanayagam
A,2011















Retrospective 7106 68.2% >65 3232/3874 Stable and unstable 30 day 7
Sam A, 2011 Spain, USA,
Switzerland
Prospective 1206 69.3±16.1 536/670 Stable and unstable 30 day 8
Chan CM, 2010 USA Retrospective 302 59.7±17.2 133/169 Stable and unstable 90 day 8
Singanayagam A,
2010
UK Retrospective 585 55.4% >65 258/327 Stable and unstable 30 day 7
Moores L, 2010 USA, Switzerland,
Spain
Retrospective 567 74% >65 245/322 Stable 30 day 7
Nordenholz K, 2011 USA Retrospective 168 53 (40–66) 72/96 Stable and unstable 30 day 7
Choi WH,2009 Korea Retrospective 90 60.4±16.0 37/53 Stable and unstable 30 day 7
Donzé J, 2008 Switzerland, France, USA Prospective 357 64±18 158/199 Stable 90 day 8
Jiménez D, 2008 Spain, USA Prospective 318 75.5% >65 136/182 Stable 30 day 8
Jiménez D, 2007
(Validation Cohort)
Spain Prospective 599 67% >65 246/353 Stable and
unstable
30 day 8
Aujesky D,2007 Switzerland, France, USA Prospective 899 64% >65 382/517 Stable and unstable 30 day 8
Zhou et al. Respiratory Research 2012, 13:111 Page 5 of 12
http://respiratory-research.com/content/13/1/111rate was 1.3% (85/6553) in patients with low-risk sPESI
Vs 2.9% (377/11605) in patients with high-risk sPESI,
the summary OR of patients with low-risk sPESI com-
pared with patients with high-risk sPESI was 0.40 (95%
CI 0.31 to 0.51; Z=7.59, P < 0.00001) (Figure 5 Above);
the pooled serious adverse events rate was 1.2% (81/
6802) in patients with low-risk PESI Vs 3.8% (384/
10016) in patients with high-risk PESI, the summary OR
of patients with low-risk PESI compared with patients
with high-risk PESI was 0.30 (95% CI 0.23 to 0.38;
Z=9.81, P < 0.00001) (Figure 5 Below).
Sensitivity analysis of primary outcome (all-cause mor-
tality) by removal the retrospective studies showed there
was no heterogeneity in the studies (I2 = 1%); the sum-
mary OR of patients with low-risk PESI compared withpatients with high-risk PESI was 0.13 (95% CI 0.10 to
0.19; Z=11.81, P < 0.00001) (Figure 6); the funnel plot
showed no asymmetry, which indicated no evidence of
publication bias (Figure 3D). Sensitivity analyses showed
the robust result of the pooled meta-analyses.Accuracy of the PESI to predict prognostic outcomes
The sensitivity and specificity for PESI in PE prognosis
diagnosis of each included studies are also shown in
Table 2.
For the outcome of all-cause mortality, the pooled sen-
sitivity was 0.909 (95% CI: 0.900 to 0.916). The pooled
specificity was 0.411 (95% CI: 0.407 to 0.415). The SROC
curve is shown in Figure 7A. The overall weighted AUC




All-cause death PE-related death Adverse outcome All-cause death PE-related death Adverse outcome
PESI low risk PESI high risk PESI low risk PESI high risk PESI low risk PESI high risk Sensitivity Specific Sensitivity Specific Sensitivity Specific
Lankeit M, 2011 sPESI 1/198 (0.5%) 26/328 (7.9%) 0/198 (0.0%) 8/328 (2.4%) 2/198 (1.0%) 29/328 (8.8%) 0.963 0.395 1.000 0.382 0.935 0.396
Sánchez D, 2011 sPESI 7/407 (1.7%) 120/884 (13.6%) 2/407 (0.5%) 58/884 (6.6%) Not mentioned Not mentioned 0.945 0.344 0.967 0.329 N/A N/A
Lankeit M, 2012 sPESI 0/165 (0.0%) 40/361 (11.1%) Not mentioned Not mentioned 3/165 (1.8%) 18/361 (5.0%) 1.000 0.340 N/A N/A 0.857 0.321
Righini M, 2011 sPESI 1/165 (0.9%) 10/192 (5.2%) 1/165 (0.9%) 6/192 (3.0%) Not mentioned Not mentioned 0.909 0.474 0.857 0.469 N/A N/A
Spirk D, 2011 sPESI 0/106 (0.0%) 16/263 (6.1%) Not mentioned Not mentioned 3/106 (2.9%) 21/263 (8.0%) 1.000 0.394 N/A N/A 0.875 0.299
Vanni S, 2011 PESI 4/145 (2.8%) 34/318 (10.7%) 1/145 (0.7%) 24/318 (7.5%) 3/145 (2.1%) 29/318 (9.1%) 0.895 0.332 0.960 0.329 0.906 0.329








0.894 0.438 N/A N/A 0.814 0.417








0.902 0.394 N/A N/A 0.799 0.372
Hariharan P, 2011 PESI Not mentioned Not mentioned Not mentioned Not mentioned 9/109 (8.3%) 54/136 (39.7%) N/A N/A N/A N/A 0.857 0.549
Jiménez D, 2011 PESI Not mentioned Not mentioned 1/199 (0.5%) 36/392 (9.2%) Not mentioned Not mentioned N/A N/A 0.973 0.357 N/A N/A
Singanayagam A,
2011
PESI 1/197 (0.5%) 22/214 (10.3%) Not mentioned Not mentioned Not mentioned Not mentioned 0.957 0.505 N/A N/A N/A N/A
Jiménez D, 2010
(Derivation Cohort)
PESI 89/4235 (2.1%) 857/6119 (14.0%) Not mentioned Not mentioned Not mentioned Not mentioned 0.906 0.411 N/A N/A N/A N/A
Jiménez D, 2010
(Derivation Cohort)
sPESI 3/305 (1.0%) 75/690 (10.9%) Not mentioned Not mentioned Not mentioned Not mentioned 0.962 0.329 N/A N/A N/A N/A
Jiménez D, 2010
(RIETE Cohort)
sPESI 28/2565 (1.1%) 404/4541 (8.9%) Not mentioned Not mentioned Not mentioned Not mentioned 0.935 0.380 N/A N/A N/A N/A
Sam A, 2011 PESI 16/431 (3.7%) 103/775 (13.3%) Not mentioned Not mentioned Not mentioned Not mentioned 0.866 0.382 N/A N/A N/A N/A
Sam A, 2011 sPESI 6/369 (1.6%) 113/837 (13.5%) Not mentioned Not mentioned 8/369 (2.2%) 34/837 (4.1%) 0.950 0.334 N/A N/A 0.810 0.310
Chan CM, 2010 PESI 0/106 (0.0%) 9/196 (4.6%) Not mentioned Not mentioned Not mentioned Not mentioned 1.000 0.362 N/A N/A N/A N/A
Singanayagam A,
2010
PESI 6/288 (2.1%) 38/297 (12.8%) Not mentioned Not mentioned Not mentioned Not mentioned 0.864 0.521 N/A N/A N/A N/A
Moores L, 2010 PESI 2/191 (1.0%) 55/376 (14.6%) 1/191 (1.5%) 33/376 (8.8%) Not mentioned Not mentioned 0.965 0.371 0.971 0.356 N/A N/A
Nordenholz K, 2011 PESI 0/91 (0.0%) 5/77 (6.5%) Not mentioned Not mentioned Not mentioned Not mentioned 1.000 0.588 N/A N/A N/A N/A
Choi WH, 2009 PESI 3/39 (7.7%) 13/51 (25.5%) Not mentioned Not mentioned Not mentioned Not mentioned 0.813 0.486 N/A N/A N/A N/A
Donzé J, 2008 PESI 2/186 (1.1%) 19/171 (11.1%) Not mentioned Not mentioned Not mentioned Not mentioned 0.905 0.548 N/A N/A N/A N/A
Jiménez D, 2008 PESI 0/100 (0.0%) 12/218 (5.5%) Not mentioned Not mentioned Not mentioned Not mentioned 1.000 0.327 N/A N/A N/A N/A
Jiménez D, 2007
(Validation Cohort)
PESI 2/216 (0.9%) 41/383 (10.7%) Not mentioned Not mentioned 6/216 (2.8%) 26/383 (6.8%) 0.953 0.385 N/A N/A 0.813 0.370
Aujesky D, 2007 PESI 5/426 (1.2%) 53/573 (9.2%) 3/426 (0.7%) 18/573 (3.1%) Not mentioned Not mentioned 0.914 0.447 0.857 0.433 N/A N/A
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Figure 2 Meta-analysis of all-cause mortality in PE with PESI low risk versus PESI high risk.
Zhou et al. Respiratory Research 2012, 13:111 Page 7 of 12
http://respiratory-research.com/content/13/1/111was 0.7853±0.0058, and the overall accuracy (Q*) was
0.7231±0.0050. While in the PESI subgroup, the pooled
sensitivity was 0.900 (95% CI: 0.889 to 0.911), the pooled
specificity was 0.411 (95% CI: 0.407 to 0.415), the SROC
curve is shown in Figure 7B, the overall weighted AUC
was 0.7856±0.0075, and the overall accuracy (Q*) was
0.7234±0.0065; in the sPESI subgroup, the pooled sensi-
tivity was 0.919 (95% CI: 0.907 to 0.930), the pooled spe-
cificity was 0.382 (95% CI: 0.376 to 0.388), the SROC
curve is shown in Figure 7C, the overall weighted AUC
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Test for overall effect: Z = 7.59 (P < 0.00001)
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Figure 3 Funnel plots for publication bias analysis. OR= odds ratio; SFor the outcome of PE-related mortality, the pooled
sensitivity was 0.953 (95% CI: 0.913 to 0.978). The pooled
specificity was 0.374 (95% CI: 0.360 to 0.388). The SROC
curve is shown in Figure 7D. The overall weighted AUC
was 0.8218±0.0349, and the overall accuracy (Q*) was
0.7552±0.0314. While in the PESI subgroup, the pooled
sensitivity was 0.949 (95% CI: 0.892 to 0.981), the pooled
specificity was 0.382 (95% CI: 0.362 to 0.401), the SROC
curve is shown in Figure 7E, the overall weighted AUC
was 0.8158±0.0451, and the overall accuracy (Q*) was
0.7498±0.0403; in the sPESI subgroup, the pooled sensi-
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Figure 4 Meta-analysis of PE-related mortality in PE with PESI low risk versus PESI high risk.
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curve is shown in Figure 7F, the overall weighted AUC
was 0.8317±0.0547, and the overall accuracy (Q*) was
0.7642±0.0501.
For the outcome of serious adverse events, the pooled
sensitivity was 0.821 (95% CI: 0.795 to 0.845). The
pooled specificity was 0.389 (95% CI: 0.384 to 0.394).
The SROC curve is shown in Figure 7G. The overall
weighted AUC was 0.6809±0.0208, and the overall ac-
curacy (Q*) was 0.6378±0.0164. While in the PESI sub-
group, the pooled sensitivity was 0.826 (95% CI: 0.788
to 0.859), the pooled specificity was 0.415 (95% CI:
0.407 to 0.422), the SROC curve is shown in Figure 7H,
the overall weighted AUC was 0.7100±0.0314, and the
overall accuracy (Q*) was 0.6609±0.0252; in the sPESI
subgroup, the pooled sensitivity was 0.816 (95% CI:
0.778 to 0.850), the pooled specificity was 0.366 (95%
CI: 0.358 to 0.373), the SROC curve is shown in
Figure 7I, the overall weighted AUC was 0.6454±0.0197,
and the overall accuracy (Q*) was 0.6101±0.0152.
Discussion
Some meta-analysis and systematic reviews have pro-
vided sufficient evidence that the prognostic outcomes
of APE can be affected by haemodynamic status, right
ventricular dysfunction, myocardial injury, and other
clinical features [37-41]. PESI was designed based on
some clinical features. Our meta-analysis showed high-
risk PESI is a risk factor for all-cause death, PE-related
death, and serious adverse events. Pooled sensitivity,
specificity, and SROC were used for predicting PEprognosis. An AUC value of 0.5 indicates that the test
has no discriminatory ability, whereas an AUC value of
1.0 indicates perfect capability [42]. While to demon-
strate excellent accuracy, the AUC should be in the re-
gion of 0.97 or above; an AUC of 0.93 to 0.96 is very
good; 0.75 to 0.92 is good; but an AUC less than 0.75
has obvious deficiencies in its accuracy [43]. Our
meta-analysis showed the overall weighted AUC for
all-cause mortality was 0.78 (95% CI: 0.77 to 0.80);
and AUC for PE-related mortality was 0.82 (95% CI:
0.75 to 0.89). PESI has good accuracy for predicting
PE prognosis. The main reason is that the PESI was
derived form multi-center large sample studies with
appropriate research methods. In the PESI study,
15,531 discharged patients with PE treated at 186 hos-
pitals were included, on the basis of the β-coefficients
of the stepwise logistic regression model, PESI with a
point score was generated [9].
Our meta-analysis showed in sPESI subgroup, the OR
of all-cause mortality, PE-related mortality, and serious
adverse events was similar to that in PESI subgroup.
Most important, in sPESI subgroup, the AUC for pre-
dicting all-cause mortality, PE-related mortality, and ser-
ious adverse events was also similar to that in PESI
subgroup. It has the same accuracy between PESI and
sPESI. The sPESI is also derived form logistic regression
analysis [10]. In the derivation data set, univariate logistic
regression of the original 11 PESI variables led to the re-
moval of variables that did not reach statistical signifi-
cance and subsequently produced the simplified PESI that
contained the variables of cancer, chronic cardiopulmonary
Figure 5 Meta-analysis of serious adverse events in PE with PESI low risk versus PESI high risk. Serious adverse events were defined as
any of the following: nonfatal recurrent PE, nonfatal recurrent DVT, nonfatal bleeding, or delayed homodynamic instability.
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Figure 6 Sensitivity analysis of all-cause mortality (primary outcome) by removal the retrospective studies.
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globin saturation levels. 11 variables in PESI reduced to 6
variables in sPESI. The sPESI does not decrease prognostic
accuracy compared with the original PESI, but sPESI is
easier to use.
In general, the performance of prognostic models
should be assessed in two ways: its discrimination and
calibration aspects. Discrimination is the ability of the
model to correctly separate the subjects into different
groups. Calibration is the degree of correspondence be-
tween the estimated probability produced by the model27 citations were identified in PubMed and EMBASE 
1 non-English article was deleted 
2 reviews were deleted 
3 studies did not meet the inclusion criteria were deleted 
21 studies were usable for meta-analysis 
0 studies were added by manually reviewing conference 
proceedings and references 
21 studies were usable for meta-analysis 
Figure 7 SROC plots for combined sensitivity and (1-specificity)
of the included studies.and the actual observed probability [6]. Discrimination is
also called predicting accuracy, which can be assessed by
sensitivity (true positive rate), and specificity (true nega-
tive rate), ROC, and AUC. Our meta-analysis has already
proved the PESI has good accuracy for predicting APE
outcomes. The calibration is also assessed by the
Hosmer-Lemeshow test [44]. But the data of the calibra-
tion was not found in the included studies. So we can’t
calculate the calibration for predicting prognosis in this
meta-analysis. Some prospective studies for accessing
PESI predicting calibration can be recommended.
Except we can’t calculated the calibration for predict-
ing prognosis in this meta-analysis, there are some other
limitations. First, Lankeit M maybe used same partici-
pants in two included studies [17] and [19], as well as
Singanayagam A’s studies [26,29], and Jiménez D’s stud-
ies [34,35]. Repeated include will increase the weight of
the studies, and maybe result bias. Second, different PE
haemodynamic status of patients included in our meta-
analysis, some included haemodynamic stable patients,
some included haemodynamic stable and unstable
patients. But this bias is small, because evaluation of
hemodynamic status is included in the PESI and sPESI.
Third, the meta-analysis can’t test the prognostic accur-
acy against other clinical score such as the Geneva prog-
nostic score. Finally, most of the included studies were
came from Europe and North America, only a study
came from Asia, no study came from Africa, South
America and Oceania. Some high-quality studies should
Zhou et al. Respiratory Research 2012, 13:111 Page 11 of 12
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worldwide.
Conclusions
Our meta-analysis identified PESI has discriminative
power to predict the short-term death and adverse out-
come events in patients with acute pulmonary embolism;
the PESI and the sPESI have similar accuracy, while sPESI
is easier to use. However, the calibration for predicting
prognosis can’t be calculated from this meta-analysis,
some prospective studies for accessing PESI predicting
calibration can be recommended.
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